220 related articles for article (PubMed ID: 21499304)
1. Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate.
Babu E; Ramachandran S; CoothanKandaswamy V; Elangovan S; Prasad PD; Ganapathy V; Thangaraju M
Oncogene; 2011 Sep; 30(38):4026-37. PubMed ID: 21499304
[TBL] [Abstract][Full Text] [Related]
2. Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate.
Thangaraju M; Karunakaran SK; Itagaki S; Gopal E; Elangovan S; Prasad PD; Ganapathy V
Cancer; 2009 Oct; 115(20):4655-66. PubMed ID: 19637353
[TBL] [Abstract][Full Text] [Related]
3. Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC.
Stockwin LH; Yu SX; Borgel S; Hancock C; Wolfe TL; Phillips LR; Hollingshead MG; Newton DL
Int J Cancer; 2010 Dec; 127(11):2510-9. PubMed ID: 20533281
[TBL] [Abstract][Full Text] [Related]
4. The Comparative Experimental Study of Sodium and Magnesium Dichloroacetate Effects on Pediatric PBT24 and SF8628 Cell Glioblastoma Tumors Using a Chicken Embryo Chorioallantoic Membrane Model and on Cells In Vitro.
Damanskienė E; Balnytė I; Valančiūtė A; Lesauskaitė V; Alonso MM; Stakišaitis D
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142368
[TBL] [Abstract][Full Text] [Related]
5. Novel molecular mechanisms of antitumor action of dichloroacetate against T cell lymphoma: Implication of altered glucose metabolism, pH homeostasis and cell survival regulation.
Kumar A; Kant S; Singh SM
Chem Biol Interact; 2012 Jul; 199(1):29-37. PubMed ID: 22705712
[TBL] [Abstract][Full Text] [Related]
6. Multi-modality imaging to assess metabolic response to dichloroacetate treatment in tumor models.
Neveu MA; De Preter G; Joudiou N; Bol A; Brender JR; Saito K; Kishimoto S; Grégoire V; Jordan BF; Krishna MC; Feron O; Gallez B
Oncotarget; 2016 Dec; 7(49):81741-81749. PubMed ID: 28082726
[TBL] [Abstract][Full Text] [Related]
7. Targeting of two aspects of metabolism in breast cancer treatment.
Gang BP; Dilda PJ; Hogg PJ; Blackburn AC
Cancer Biol Ther; 2014; 15(11):1533-41. PubMed ID: 25482950
[TBL] [Abstract][Full Text] [Related]
8. Synergistic anticancer potential of dichloroacetate and estradiol analogue exerting their effect via ROS-JNK-Bcl-2-mediated signalling pathways.
Stander XX; Stander BA; Joubert AM
Cell Physiol Biochem; 2015; 35(4):1499-526. PubMed ID: 25791820
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
[TBL] [Abstract][Full Text] [Related]
10. SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases.
Thangaraju M; Gopal E; Martin PM; Ananth S; Smith SB; Prasad PD; Sterneck E; Ganapathy V
Cancer Res; 2006 Dec; 66(24):11560-4. PubMed ID: 17178845
[TBL] [Abstract][Full Text] [Related]
11. Antitumor and chemosensitizing action of dichloroacetate implicates modulation of tumor microenvironment: a role of reorganized glucose metabolism, cell survival regulation and macrophage differentiation.
Kumar A; Kant S; Singh SM
Toxicol Appl Pharmacol; 2013 Nov; 273(1):196-208. PubMed ID: 24051182
[TBL] [Abstract][Full Text] [Related]
12. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers.
Li H; Myeroff L; Smiraglia D; Romero MF; Pretlow TP; Kasturi L; Lutterbaugh J; Rerko RM; Casey G; Issa JP; Willis J; Willson JK; Plass C; Markowitz SD
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8412-7. PubMed ID: 12829793
[TBL] [Abstract][Full Text] [Related]
13. The plasma membrane transporter SLC5A8 suppresses tumour progression through depletion of survivin without involving its transport function.
Coothankandaswamy V; Elangovan S; Singh N; Prasad PD; Thangaraju M; Ganapathy V
Biochem J; 2013 Feb; 450(1):169-78. PubMed ID: 23167260
[TBL] [Abstract][Full Text] [Related]
14. Mito-DCA: a mitochondria targeted molecular scaffold for efficacious delivery of metabolic modulator dichloroacetate.
Pathak RK; Marrache S; Harn DA; Dhar S
ACS Chem Biol; 2014 May; 9(5):1178-87. PubMed ID: 24617941
[TBL] [Abstract][Full Text] [Related]
15. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
[TBL] [Abstract][Full Text] [Related]
16. Suppression of Pyruvate Dehydrogenase Kinase by Dichloroacetate in Cancer and Skeletal Muscle Cells Is Isoform Specific and Partially Independent of HIF-1α.
Škorja Milić N; Dolinar K; Miš K; Matkovič U; Bizjak M; Pavlin M; Podbregar M; Pirkmajer S
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445316
[TBL] [Abstract][Full Text] [Related]
17. Sodium-coupled transport of the short chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer.
Thangaraju M; Cresci G; Itagaki S; Mellinger J; Browning DD; Berger FG; Prasad PD; Ganapathy V
J Gastrointest Surg; 2008 Oct; 12(10):1773-81; discussion 1781-2. PubMed ID: 18661192
[TBL] [Abstract][Full Text] [Related]
18. Use of hyperpolarized [1-13C]pyruvate and [2-13C]pyruvate to probe the effects of the anticancer agent dichloroacetate on mitochondrial metabolism in vivo in the normal rat.
Hu S; Yoshihara HA; Bok R; Zhou J; Zhu M; Kurhanewicz J; Vigneron DB
Magn Reson Imaging; 2012 Dec; 30(10):1367-72. PubMed ID: 22819176
[TBL] [Abstract][Full Text] [Related]
19. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter.
Gupta N; Martin PM; Prasad PD; Ganapathy V
Life Sci; 2006 Apr; 78(21):2419-25. PubMed ID: 16375929
[TBL] [Abstract][Full Text] [Related]
20. Metformin enhances cytotoxic action of dichloroacetate against Lewis lung carcinoma cells in vitro.
Kolesnik DL; Pyaskovskaya ON; Gorbach O; Solyanik GI
Exp Oncol; 2020 Mar; 42(1):35-39. PubMed ID: 32231186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
